After completing her medical studies in Rome and a postdoctoral fellowship at the National Cancer Institute in Bethesda (USA), Dr Alteri spent 25 years in the pharmaceutical industry, where she was involved in major projects that yielded important drugs such as Gleevec for myeloid leukaemia, Coartem for malaria and Reyataz for HIV-AIDS.
In 2012 she joined the European Medicines Agency, where she was Head of Human Medicines R&D support Division, and member of the Executive Board. In these roles, Dr Alteri was part of many high impact EMA’s initiatives, from the transparency of clinical trial data to the development of regulatory science strategy to 2025.
Dr Alteri is currently a member of the Scientific Committee and faculty of the master course in Drug R&D of the University of Geneva, and master courses in R&D at the Luiss University and Universita’ Cattolica in Rome. Recently Dr Alteri has been appointed Core Member of the Unitaid Proposal Review Team.
In addition, Dr Alteri is a member of CIOMS working group Real World Data and Education.